Diuretic treatment and diuretic resistance in heart failure

American Journal of Medicine

Volumn 106, Issue 1, 1999, Pages 90-96

  Krämer, Bernhard K ^a,b   Schweda, Frank ^a   Riegger, Günter A J ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT;

BLOOD VOLUME; EDEMA; FLUID INTAKE; HEART FAILURE; HYPONATREMIA; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; SALT INTAKE; SODIUM RETENTION;

DIURETICS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; HYPONATREMIA; KIDNEY FAILURE, CHRONIC;

EID: 0032983840     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00365-9     Document Type: Review

References (70)

1. Levy D., Larson M.G., Vasan R.S., et al. The progression from hypertension to congestion heart failure. J Am Med Assoc. 275:1996;1557-1562.
2. Dahlöf B., Lindholm L.H., Hansson L., et al. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet. 338:1991;1281-1285.
3. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Eldery Program (SHEP). J Am Med Assoc. 265:1991;3255-3264.
4. Gottdiener J.S., Reda D.J., Massie B.M., et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation. 95:1997;2007-2014.
5. Dikshit K., Vyden J.K., Forrester J.S., et al. Renal and extrarenal effects of furosemide in congestive heart failure after acute myocardial infarction. NEJM. 288:1973;1087-1090.
6. Silke B. Haemodynamic impact of diuretic therapy in chronic heart failure. Cardiology. 84:(suppl 2):1994;115-123.
7. Johnston G.D., Hiatt W.R., Nies A.S., et al. Factors modifying the early nondiuretic vascular effects of furosemide in man. The possible role of renal prostaglandins. Circ Res. 53:1983;630-635.
8. Hasenfuß G., Holubarsch C., Herzog C., et al. Influence of cardiac function on the diuretic and hemodynamic effects of the loop diuretic piretanide. Clin Cardiol. 10:1987;83-89.
9. Wilson J.R., Reicheek N., Dunkman W.B., Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 70:1981;234-239.
10. Düsing R., Piesche L. Second line therapy of congestive heart failure with torsemide. Progr Pharmacol Clin Pharmacol. 8:1990;105-120.
11. Stauch M., Stiehl L. Controlled double-blind clinical trial of the efficacy and tolerance of torsemide in comparison with furosemide in patients with congestive heart failure. Progr Pharmacol Clin Pharmacol. 8:1990;121-126.
12. Anand I.S., Kalra G.S., Harris P., et al. Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience. 2:1991;273-278.
13. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). NEJM. 316:1987;1429-1435.
14. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. NEJM. 335:1996;1107-1114.
15. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). Am J Cardiol. 78:1996;902-907.
16. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. NEJM. 334:1996;1349-1355.
17. The effect of digoxin on mortality and morbidity in patients with heart failure. NEJM. 336:1997;525-533.
18. Lancet. 342:1993;1441-1446.
19. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. NEJM. 325:1991;293-302.
20. J Am Coll Cardiol. 18:1991;1602-1609.
21. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. NEJM. 327:1992;685-691.
22. Sharpe N., Murphy J., Smith H., Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. i:1988;255-259.
23. The treatment of heart failure. Eur Heart J. 18:1997;736-753.
24. Cotter G., Metzkor E., Kaluski E., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 351:1998;389-393.
25. Dzau V.J., Colucci W.S., Williams G.H., et al. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. NEJM. 302:1989;1373-1379.
26. Anand I.S., Ferrari R., Kalra G.S., et al. Edema of cardiac origin studies of body water and sodium, renal function, hemodynamic indexes and plasma hormones in untreated congestive cardiac failure . Circulation. 80:1989;299-305.
27. Anand I.S., Veal N.B., Kalra G.S., et al. Treatment of heart failure with diuretics body compartments, renal functions and plasma hormones . Eur Heart J. 10:1989;445-450.
28. Fliser D., Franek E., Joest M., et al. Renal function in the elderly impact of hypertension and cardiac function . Kidney Int. 51:1997;1196-1204.
29. Risler T., Krämer B., Müller G.A. The efficacy of diuretics in acute and chronic renal failure. Drugs. 41:(suppl 3):1991;69-79.
30. Friedman E., Shadel M., Halkin H., Farfel Z. Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann Intern Med. 110:1989;24-30.
31. Riegger G.A.J., Liebau G., Kochsiek K. Antidiuretic hormone in congestive heart failure. Am J Med. 72:1982;49-52.
32. Lee W.H., Packer M. Prognostic importance of serum sodium concentration and its modification by commencing enzyme inhibition in patients with severe chronic heart failure. Circulation. 73:1986;257-267.
33. Vasko M.R., Brown-Cartwright D., Knochel J.P., et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 102:1985;314-318.
34. Offerhaus L. Drug interaction at excretory mechanisms. Pharmacol Ther. 15:1981;69-78.
35. Eiskjaer H., Bagger J.P., Danielsen H., et al. Mechanisms of sodium retention in heart failure relation to the renin-angiotensin-aldosterone system . Am J Physiol. 260:1991;F883-F889.
36. Laragh J.H. Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. NEJM. 313:1985;1330-1340.
37. Smith J.B., Lincoln T.M. Angiotensin decreases cyclic GMP accumulation produced by atrial natriuretic factor. Am J Physiol. 253:1987;C147-C150.
38. Schiffrin E.L. Decreased density of binding sites for atrial natriuretic peptide on platelets of patients with severe congestive heart failure. Clin Sci. 74:1988;213-218.
39. Cavero P.G., Margulies K.B., Winaver J., et al. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation. 82:1990;196-201.
40. Eiskjaer H., Bagger J.P., Danielsen H., et al. Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in man. Int J Cardiol. 33:1991;61-74.
41. Volpe M., Magri P., Rao M.A.E., et al. Intrarenal determinants of sodium retention in mild heart failure. Effect of angiotensin-converting enzyme inhibition. Hypertension. 30:1997;168-176.
42. Martin P.Y., Schrier R.W. Sodium and water retention in heart failure pathogenesis and treatment . Kidney Int. 51:(suppl 59):1997;57-61.
43. Kaissling B., Stanton B.A. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am J Physiol. 255:1988;F1256-F1268.
44. + and K+ transport. Am J Physiol. 225:1988;F1269-F1275.
45. Brater D.C., Chennavasin P., Seiwell R. Furosemide in patients with heart failure shift in dose-response curves . Clin Pharmacol Ther. 28:1989;182-186.
46. Wilcox C.S., Mitch W.E., Kelly R.A., et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med. 102:1983;450-458.
47. Brater DC, Sundblad KJ, Becker PK, et al. Diuretic duration and prevention of sodium retention. (Abstr.) In: Heart Failure 1997. Second International Meeting of the Working Group on Heart Failure. Cologne, Germany May 24-27, 1997:82.
48. Dzau V.J., Hollenberg N.K. Renal response to captopril in severe heart failure role of furosemide in natriuresis and reversal of hyponatremia . Ann Intern Med. 100:1984;777-782.
49. Motwani J.G., Fenwick M.K., Morton J.J., Struthers A.D. Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure. Circulation. 86:1992;439-445.
50. Good J.M., Brady A.J.B., Noormohamed F.H., et al. Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition. Circulation. 90:1994;220-224.
51. Ellison D.H. The physiologic basis of diuretic synergism its role in treating diuretic resistance . Ann Intern Med. 114:1991;886-894.
52. Fliser D., Schröter M., Neubeck M., Ritz E. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 46:1994;482-488.
53. Knauf H., Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 29:1997;367-372.
54. Dormans T.P., Gerlag P.G. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J. 17:1996;1867-1874.
55. Van Vliet A.A., Donker A.J.M., Nauta J.J.P., Verheugt F.W.A. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 71:1993;21A-28A.
56. Struthers A.D. Aldosterone escape during ACE inhibitor treatment in chronic heart failure. Eur Heart J. 16:(suppl N):1995;103-106.
57. Rudy D.W., Voelker J.R., Greene P.K., et al. Loop diuretics for chronic renal insufficiency a continuous infusion is more efficacious than bolus therapy . Ann Intern Med. 115:1991;360-366.
58. Van Meyel J.J.M., Smits P., Dormans T., et al. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med. 235:1994;329-334.
59. Kramer W.G., Smith W.B., Ferguson J., et al. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. J Clin Pharmacol. 36:1996;265-270.
60. Gerlag P., Van Meijel J.J. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med. 148:1988;286-291.
61. Marangoni E., Oddone A., Surian M., et al. Effect of high-dose furosemide in refractory congestive heart failure. Angiology. 41:1990;862-868.
62. Lahav M., Regev A., Rà anani P., Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest. 102:1992;725-731.
63. Herchuelz A., Derenne F., Deger F., et al. Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics modulation by sodium balance . J Pharmacol Exp Ther. 248:1989;1175-1181.
64. Riegger G.A.J., Kahles H.W., Elsner D., et al. Effects of acetylsalicylic acid on renal function in patients with chronic heart failure. Am J Med. 90:1991;571-575.
65. Thompson B.T., Cockrill B.A. Renal-dose dopamine a siren song? Lancet. 344:1994;7-8.
66. Denton M.D., Chertow G.M., Brady H.R. "Renal dose" dopamine for the treatment of acute renal failure scientific rationale, experimental studies and clinical trials . Kidney Int. 49:1996;4-14.
67. Vargo D.L., Brater D.C., Rudy D.W., Swan S.K. Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure. J Am Soc Nephrol. 7:1996;1032-1037.
68. Elsner D., Müntze A., Kromer E.P., Riegger G.A.J. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol. 82:1992;196-201.
69. Good J.M., Peters M., Wilkins M., et al. Renal response to candoxatrilat in patients with heart failure. J Am Coll Cardiol. 25:1995;1273-1281.
70. Nishikimi T., Kawano Y., Saito Y., Matsuoka H. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats. J Cardiovasc Pharmacol. 27:1996;275-282.